NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 3 FDA
NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 2 FDA
NCT03112603 2025-08-12A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Incyte CorporationPhase 3 Completed330 enrolled 32 charts 2 FDA
NCT03640481 2024-12-12Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapySanofiPhase 2 Terminated159 enrolled 25 charts 2 FDA
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 2 FDA
NCT02195869 2019-07-11Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseasePharmacyclics LLC.Phase 1/2 Completed45 enrolled 13 charts 2 FDA